ストックスクリーナーアプリを入手
0.1106
13.44%
0.0131
前日終値:
$0.0975
開ける：
$0.0975
24時間の取引高:
98.14M
Relative Volume:
28.47
時価総額：
$2.42M
収益：
-
当期純損益:
$-66.07M
株価収益率:
-0.00817
EPS:
-13.5424
ネットキャッシュフロー:
$-3.11M
1週間 パフォーマンス:
-12.22%
1か月 パフォーマンス:
-13.05%
6か月 パフォーマンス:
-93.61%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.0975
$0.178
1週間の範囲:
$0.095
$0.178
52週間の値動き範囲:
$0.095
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
名前
Propanc Biopharma Inc
セクター
電話
61-03-9882-0780
住所
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Compare PPCB vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
1.82 | 2.55B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
19.85 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.70 | 356.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
5.81 | 315.27M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
46.21 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc (PPCB) 最新ニュース
Trending Industry Today: Propanc Biopharma Leads Gains In ETH-Holding Companies Stocks - Moomoo
The selling point was good, but there's still a loss. This money can't be used to average down. - Moomoo
Propanc Biopharma Incfiles to offer resale of up to 15 million shares of common stock by selling stockholderSEC filing - marketscreener.com
Propanc Biopharma (PPCB) files S-1 for 15M-share resale from Series C preferred - Stock Titan
PPCB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Propanc Biopharma (PPCB) approves restricted grants, reverse split 1:10–1:30 - Stock Titan
Propanc Biopharma, Inc. (PPCB) - Minichart
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain - BioSpace
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer - GlobeNewswire
Propanc extends 17-year Spain research tie to study aging and cancer - Stock Titan
Propanc Biopharma (PPCB) approves 33M shares and 1:10–1:30 reverse split - Stock Titan
Propanc Biopharma | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Propanc & Fyonibio Launch Assay for Phase 1b Human Study - The Clinical Trial Vanguard
PPCB Should I Buy - Intellectia AI
Propanc Biopharma (PPCB) Stock Analysis Report | Financials & Insights - Benzinga España
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy - Bitget
13% survival in pancreatic cancer; Propanc therapy hits >85% tumor inhibition - Stock Titan
Propanc Biopharma signs contract for Phase 1b cancer trial assay By Investing.com - Investing.com Canada
Propanc Biopharma contracts FyoniBio for drug assay development By Investing.com - Investing.com South Africa
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study - Bitget
Propanc Biopharma contracts FyoniBio for drug assay development - Investing.com
Propanc Biopharma signs contract for Phase 1b cancer trial assay - Investing.com
Propanc Biopharma Executes Service Agreement with FyoniBio - GlobeNewswire
Propanc Biopharma's lead asset PRP shows >85% tumor growth inhibition in preclinical pancreatic models - marketscreener.com
Propanc Biopharma highlights potential of lead asset PRP - TipRanks
Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic Models - TradingView
Deadliest cancer stuck at 13% survival: new PRP therapy targets spread - Stock Titan
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement By Investing.com - Investing.com South Africa
Propanc Biopharma Announces Board Change and New Appointment - TipRanks
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement - Investing.com Nigeria
Propanc Biopharma (PPCB) adds oncology expert Ralf Brandt to board as Kenyon retires - Stock Titan
Propanc Biopharma | EFFECT: Others - Moomoo
[EFFECT] Propanc Biopharma, Inc. SEC Filing - Stock Titan
Propanc Biopharma files four new patent applications for cancer treatment By Investing.com - Investing.com South Africa
Propanc Biopharma files four new patent applications for cancer treatment - Investing.com
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results - The Manila Times
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
Certain Warrants of Propanc Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 10-FEB-2026. - marketscreener.com
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market - The Manila Times
Lab tests: Propanc’s PRP slowed tumor growth 85%, human trial planned - Stock Titan
Propanc Biopharma files fourth patent application in two months By Investing.com - Investing.com Australia
Propanc Biopharma files fourth patent application in two months - Investing.com
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations - marketscreener.com
Propanc Biopharma Accelerates IP Momentum: Files Fourth - GlobeNewswire
PPCB Forecast — Price Prediction for 2026. Should I Buy PPCB? - Intellectia AI
Propanc Biopharma files new patent for synthetic cancer treatment - Investing.com
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - The Manila Times
Propanc Biopharma, Inc. Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - marketscreener.com
Propanc Biopharma files new patent for synthetic cancer treatment By Investing.com - Investing.com Canada
Propanc Biopharma advances pancreatic cancer treatment toward clinical trials By Investing.com - Investing.com Nigeria
PPCB (PPCB) Stock Price, News & Analysis - MarketBeat
Propanc Biopharma Inc (PPCB) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):